Manto MU. The wide spectrum of spinocerebellar ataxias (SCAs). Cerebellum. 2005;4:2–6. https://doi.org/10.1080/14734220510007914.
Article CAS PubMed Google Scholar
Schmahmann JD, Weilburg JB, Sherman JC. The neuropsychiatry of the cerebellum - insights from the clinic. Cerebellum. 2007;6:254–67. https://doi.org/10.1080/14734220701490995.
Manto M, Marmolino D. Animal models of human cerebellar ataxias: a cornerstone for the therapies of the twenty-first century. Cerebellum. 2009;8:137–54. https://doi.org/10.1007/s12311-009-0127-3.
Bodranghien F, Bastian A, Casali C, Hallett M, Louis ED, Manto M, et al. Consensus Paper: Revisiting the Symptoms and Signs of Cerebellar Syndrome. Cerebellum. 2016;15:369–91. https://doi.org/10.1007/s12311-015-0687-3.
Article PubMed PubMed Central Google Scholar
Jones TM, Shaw JD, Sullivan K, Zesiewicz TA. Treatment of cerebellar ataxia. Neurodegener Dis Manag. 2014;4:379–92. https://doi.org/10.2217/nmt.14.27.
Ilg W, Bastian AJ, Boesch S, Burciu RG, Celnik P, Claassen J, et al. Consensus paper: management of degenerative cerebellar disorders. Cerebellum. 2014;13:248–68. https://doi.org/10.1007/s12311-013-0531-6.
Article CAS PubMed PubMed Central Google Scholar
Power EM, Empson RM. Functional contributions of glutamate transporters at the parallel fibre to Purkinje neuron synapse-relevance for the progression of cerebellar ataxia. Cerebellum Ataxias. 2014;1:3. https://doi.org/10.1186/2053-8871-1-3.
Article PubMed PubMed Central Google Scholar
Revuelta GJ, Wilmot GR. Therapeutic interventions in the primary hereditary ataxias. Curr Treat Options Neurol. 2010;12:257–73. https://doi.org/10.1007/s11940-010-0075-8.
Rodriguez-Lebron E, Costa Mdo C, Luna-Cancalon K, Peron TM, Fischer S, Boudreau RL, et al. Silencing mutant ATXN3 expression resolves molecular phenotypes in SCA3 transgenic mice. Mol Ther. 2013;21:1909–18. https://doi.org/10.1038/mt.2013.152.
Article CAS PubMed PubMed Central Google Scholar
Nobrega C, Nascimento-Ferreira I, Onofre I, Albuquerque D, Hirai H, Deglon N, et al. Silencing mutant ataxin-3 rescues motor deficits and neuropathology in Machado-Joseph disease transgenic mice. PLoS One. 2013;8:e52396. https://doi.org/10.1371/journal.pone.0052396.
Article ADS CAS PubMed PubMed Central Google Scholar
Chort A, Alves S, Marinello M, Dufresnois B, Dornbierer JG, Tesson C, et al. Interferon beta induces clearance of mutant ataxin 7 and improves locomotion in SCA7 knock-in mice. Brain. 2013;136:1732–45. https://doi.org/10.1093/brain/awt061.
Wang HL, Hu SH, Chou AH, Wang SS, Weng YH, Yeh TH. H1152 promotes the degradation of polyglutamine-expanded ataxin-3 or ataxin-7 independently of its ROCK-inhibiting effect and ameliorates mutant ataxin-3-induced neurodegeneration in the SCA3 transgenic mouse. Neuropharmacology. 2013;70:1–11. https://doi.org/10.1016/j.neuropharm.2013.01.006.
Article CAS PubMed Google Scholar
Scoles DR, Meera P, Schneider MD, Paul S, Dansithong W, Figueroa KP, et al. Antisense oligonucleotide therapy for spinocerebellar ataxia type 2. Nature. 2017;544:362–6. https://doi.org/10.1038/nature22044.
Article ADS CAS PubMed PubMed Central Google Scholar
Maiorana N, Guidetti M, Dini M, Priori A, Ferrucci R. Cerebellar tDCS as therapy for cerebellar ataxias. Cerebellum. 2022;21:755–61. https://doi.org/10.1007/s12311-021-01357-1.
Manto M, Argyropoulos GPD, Bocci T, Celnik PA, Corben LA, Guidetti M, et al. Consensus paper: novel directions and next steps of non-invasive brain stimulation of the cerebellum in health and disease. Cerebellum. 2022;21:1092–122. https://doi.org/10.1007/s12311-021-01344-6.
Manto M, Cendelin J, Strupp M, Mitoma H. Advances in cerebellar disorders: pre-clinical models, therapeutic targets, and challenges. Expert Opin Ther Targets. 2023;27:965–87. https://doi.org/10.1080/14728222.2023.2263911.
Manto M, Gandini J, Feil K, Strupp M. Cerebellar ataxias: an update. Curr Opin Neurol. 2020;33:150–60. https://doi.org/10.1097/wco.0000000000000774.
Mitoma H, Manto M. The physiological basis of therapies for cerebellar ataxias. Ther Adv Neurol Disord. 2016;9:396–413. https://doi.org/10.1177/1756285616648940.
Article CAS PubMed PubMed Central Google Scholar
Cendelin J, Mitoma H, Manto M. Neurotransplantation therapy and cerebellar reserve. CNS Neurol Disord Drug Targets. 2018;17:172–83. https://doi.org/10.2174/1871527316666170810114559.
Article CAS PubMed Google Scholar
Mitoma H, Buffo A, Gelfo F, Guell X, Fucà E, Kakei S, et al. Consensus paper. Cerebellar reserve: from cerebellar physiology to cerebellar disorders. Cerebellum. 2020;19:131–53. https://doi.org/10.1007/s12311-019-01091-9
Triarhou LC, Zhang W, Lee WH. Graft-induced restoration of function in hereditary cerebellar ataxia. NeuroReport. 1995;6:1827–32.
Article CAS PubMed Google Scholar
Triarhou LC, Zhang W, Lee WH. Amelioration of the behavioral phenotype in genetically ataxic mice through bilateral intracerebellar grafting of fetal Purkinje cells. Cell Transplant. 1996;5:269–77.
Article CAS PubMed Google Scholar
Kaemmerer WF, Low WC. Cerebellar allografts survive and transiently alleviate ataxia in a transgenic model of spinocerebellar ataxia type-1. Exp Neurol. 1999;158:301–11. https://doi.org/10.1006/exnr.1999.7099.
Article CAS PubMed Google Scholar
Babuska V, Houdek Z, Tuma J, Purkartova Z, Tumova J, Kralickova M, et al. Transplantation of embryonic cerebellar grafts improves gait parameters in ataxic lurcher mice. Cerebellum. 2015;14:632–41. https://doi.org/10.1007/s12311-015-0656-x.
Article CAS PubMed Google Scholar
Nakamura T, Honda M, Kimura S, Tanabe M, Oda S, Ono H. Taltirelin improves motor ataxia independently of monoamine levels in rolling mouse nagoya, a model of spinocerebellar atrophy. Biol Pharm Bull. 2005;28:2244–7. https://doi.org/10.1248/bpb.28.2244.
Article CAS PubMed Google Scholar
Tsai YA, Liu RS, Lirng JF, Yang BH, Chang CH, Wang YC, et al. Treatment of spinocerebellar ataxia with mesenchymal stem cells: a phase I/IIa clinical study. Cell Transplant. 2017;26:503–12. https://doi.org/10.3727/096368916x694373.
Article PubMed PubMed Central Google Scholar
Rossi F, Cattaneo E. Opinion: neural stem cell therapy for neurological diseases: dreams and reality. Nat Rev Neurosci. 2002;3:401–9. https://doi.org/10.1038/nrn809.
Article CAS PubMed Google Scholar
Cendelin J, Buffo A, Hirai H, Magrassi L, Mitoma H, Sherrard R, et al. Task force paper on cerebellar transplantation: are we ready to treat cerebellar disorders with cell therapy? Cerebellum. 2019;18:575–92. https://doi.org/10.1007/s12311-018-0999-1.
Article CAS PubMed Google Scholar
Cendelin J. Transplantation and stem cell therapy for cerebellar degenerations. Cerebellum. 2016;15:48–50. https://doi.org/10.1007/s12311-015-0697-1.
Article CAS PubMed Google Scholar
Sotelo C, Alvarado-Mallart RM. Embryonic and adult neurons interact to allow Purkinje cell replacement in mutant cerebellum. Nature. 1987;327:421–3. https://doi.org/10.1038/327421a0.
Article ADS CAS PubMed Google Scholar
Triarhou LC, Norton J, Ghetti B. Anterograde transsynaptic degeneration in the deep cerebellar nuclei of Purkinje cell degeneration (pcd) mutant mice. Exp Brain Res. 1987;66:577–88.
Article CAS PubMed Google Scholar
Purkartova Z, Tichanek F, Kolinko Y, Cendelin J. Embryonic cerebellar graft morphology differs in two mouse models of cerebellar degeneration. Cerebellum. 2019;18:855–65. https://doi.org/10.1007/s12311-019-01067-9.
Article CAS PubMed Google Scholar
Kohsaka S, Takayama H, Ueda T, Toya S, Tsukada Y. Reorganization of cerebellar cell suspension transplanted into the weaver mutant cerebellum and immunohistochemical detection of synaptic formation. Neurosci Res. 1988;6:162–6.
Article CAS PubMed Google Scholar
Takayama H, Toya S, Shinozaki T, Inoue H, Otani M, Kohsaka S, et al. Possible synapse formation by embryonic cerebellar tissue grafted into the cerebellum of the weaver mutant mouse. Acta Neurochir Suppl (Wien). 1988;43:154–8.
Fuca E, Guglielmotto M, Boda E, Rossi F, Leto K, Buffo A. Preventive motor training but not progenitor grafting ameliorates cerebellar ataxia and deregulated autophagy in tambaleante mice. Neurobiol Dis. 2017;102:49–59.
留言 (0)